Intellia Therapeutics, Inc.
Pagina dedicata companiei Intellia Therapeutics, Inc. listata cu simbolul US.NTLA
Descriere companie[edit | ]
Intellia Therapeutics, Inc. (http://www.intelliatx.com/) is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. The Company's CRISPR/Cas9 is a technology for genome editing, process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To fully realize the transformative potential of CRISPR/Cas9, the Company uses two primary approaches. The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which its delivery technology enables precise editing of disease-causing genes directly within specific target tissues. The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Grafic actiuni companie[edit | ]